Treatment of bolivian mucosal leishmaniasis with miltefosine

Clinical Infectious Diseases

Volumn 44, Issue 3, 2007, Pages 350-356

  Soto, J ^a,c   Tolado, J ^a   Valda, L ^b   Balderrama, M ^c   Rea, I ^c   Parra, R ^c   Ardiles, J ^b,e   Soto, P ^a   Gomez A ^d   Molleda, F ^b   Fuentelsaz, C ^b   Anders, G ^e   Sindermann, H ^e   Engel, J ^e   Berman, J ^c  

^a Consorcio de Investigaciones Bioclinicas ^*  (Colombia)

^b Hospital de Clínicas   (Mexico)

^c Proyecto Oscar ^*  (United States)

^d Hospital Local   (Bolivia)

^e Zentaris GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIMONY; MILTEFOSINE;

ADULT; ANAPHYLAXIS; ARTICLE; BOLIVIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY FUNCTION TEST; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; PERU; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; ANIMALS; ANTIPROTOZOAL AGENTS; BOLIVIA; FEMALE; HUMANS; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, MUCOCUTANEOUS; MALE; PHOSPHORYLCHOLINE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33846454010     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510588     Document Type: Article

References (14)

1. Marsden PD. Mucosal leishmaniasis. Trans R Soc Trop Med Hyg 1986; 80:859-76.
2. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366:1561-77.
3. Carvalho EM, Johnson WD, Barreto E, et al. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 1985; 135:4144-8.
4. Marsden PD, Badaro R, Netto EM, Casler JD. Spontaneous clinical resolution without specific treatment in mucosal leishmaniasis. Trans R Soc Trop Med Hyg 1991; 85:221.
5. Franke ED, Wignall FS, Cruz ME, et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 1990; 113: 934-40.
6. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341: 1795-800.
7. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-46.
8. Soto J, Arana B, Toledo J, et al. Miltefosine for New World cutaneous leishmaniasis: placebo-controlled multicenter study. Clin Infect Dis 2004; 38:1266-72.
9. Kreutzer RD, Semko ME, Hendricks LD, et al. Identification of Leishmania spp by multiple isozyme analysis. Am J Trop Med Hyg 1983; 32:703-15.
10. Oliveira-Neto MP, Mattos M, Pirmez C, de Sousa CFS, Junior GG. Mucosal leishmaniasis (espundia) responsive to low dose of n-methyl glucamine (glucantime) in Rio de Janeiro, Brazil. Rev Inst Med Trop São Paulo 2000; 42:321-5.
11. Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C. A low dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow up studies (up to 10 years). Am J Trop Med Hyg 1997; 57:651-5.
12. Llanos-Cuentas A, Echevaria J, Cruz M, et al. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis 1997; 25:677-84.
13. Rodriquez LV, Dedet J-P, Paredes V, Mendoza C, Cardenas F. A randomized trial of amphotericin B alone or in combination with itraconazole in the treatment of mucocutaneous leishmaniasis. Mem Inst Oswaldo Cruz 1995; 90:525-8.
14. Davies CR, Reithinger R, Campbell-Lendrum D, Feliciangeli D, Borges R, Rodriguez N. The epidemiology and control of leishmaniasis in Andean countries. Cad Saude Publica 2000; 16:925-50.